Protagonist Therapeutics
PTGX
66 hedge funds and large institutions have $208M invested in Protagonist Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 13 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
10% more capital invested
Capital invested by funds: $189M → $208M (+$19.2M)
9.09% more ownership
Funds ownership: 64.51% → 73.6% (+9.1%)
3% more funds holding
Funds holding: 64 → 66 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.22M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$6.54M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.69M |
| 4 |
JP Morgan Chase
New York
|
+$3.07M |
| 5 |
VMI
VHCP Management III
New York
|
+$2.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$5.53M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.21M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.05M |
| 4 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$1.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.08M |
PTGX Hedge Fund Activity: Q2 2019 in Review
66 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2019, worth a combined $208M — up 10% from $189M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PTGX positions and 13 closed out — a net gain of 2 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $8.22M. The largest seller was Ghost Tree Capital, cutting an estimated $5.53M.
- 66 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2019, up from 64 in Q1 2019.
- Funds reported $208M of Protagonist Therapeutics stock for Q2 2019, up 10% quarter-over-quarter.
- 15 funds opened new Protagonist Therapeutics positions in Q2 2019 and 13 closed out, a net change of +2 holders.
- The largest Protagonist Therapeutics buyer in Q2 2019 was BlackRock, an estimated $8.22M added.
- The largest Protagonist Therapeutics seller in Q2 2019 was Ghost Tree Capital, an estimated $5.53M sold.
Based on aggregated 13F filings for Q2 2019.